Successful treatment with cefiderocol for compassionate use in a critically ill patient with XDR Acinetobacter baumannii and KPC-producing Klebsiella pneumoniae: a case reportEnrico Maria Trecarichi, Francesco Picicco, Angela Quirino et al.|Journal of Antimicrobial Chemotherapy|2019Cited by 61
Cefiderocol-Based versus Colistin-Based Regimens for Severe Carbapenem-Resistant Acinetobacter baumannii Infections: A Propensity Score-Weighted, Retrospective Cohort Study during the First Two Years of the COVID-19 PandemicMaria Mazzitelli, Anna Maria Cattelan, Darío Gregori et al.|Microorganisms|2023Cited by 41
Use of isavuconazole in critically ill patients in intensive care units: a prospective, observational, multicentre, cohort studyDaniele Roberto Giacobbe, Giovanna Travi, Elisabetta Blasi Vacca et al.|JAC-Antimicrobial Resistance|2025Cited by 4
Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremiaAlessandro Russo, Fabrizio Bar, Sara Palma Gullì et al.|Journal of Infection|2026Cited by 3
Use of a molecular syndromic panel for the etiological diagnosis of ventilator-associated bacterial pneumonia: impact on clinical outcomes and antibiotic use from a multicenter, prospective studyDaniele Roberto Giacobbe, Małgorzata Mikulska, Greta Cattardico et al.|Critical Care|2025Cited by 2